Critical Survey: RegeneRx Biopharmaceuticals (RGRX) and Biodel (ALBO)

RegeneRx Biopharmaceuticals (OTCMKTS: RGRX) and Biodel (NASDAQ:ALBO) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, earnings, risk and dividends.

Institutional and Insider Ownership

0.2% of RegeneRx Biopharmaceuticals shares are owned by institutional investors. Comparatively, 29.2% of Biodel shares are owned by institutional investors. 12.1% of RegeneRx Biopharmaceuticals shares are owned by company insiders. Comparatively, 22.3% of Biodel shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Risk & Volatility

RegeneRx Biopharmaceuticals has a beta of -2.78, indicating that its stock price is 378% less volatile than the S&P 500. Comparatively, Biodel has a beta of 1.43, indicating that its stock price is 43% more volatile than the S&P 500.


This table compares RegeneRx Biopharmaceuticals and Biodel’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
RegeneRx Biopharmaceuticals -1,539.62% -23.23% -170.89%
Biodel N/A N/A N/A

Analyst Recommendations

This is a summary of current ratings and target prices for RegeneRx Biopharmaceuticals and Biodel, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
RegeneRx Biopharmaceuticals 0 0 1 0 3.00
Biodel 0 0 6 0 3.00

RegeneRx Biopharmaceuticals presently has a consensus target price of $1.50, suggesting a potential upside of 581.82%. Biodel has a consensus target price of $61.67, suggesting a potential upside of 164.44%. Given RegeneRx Biopharmaceuticals’ higher probable upside, equities analysts clearly believe RegeneRx Biopharmaceuticals is more favorable than Biodel.

Earnings and Valuation

This table compares RegeneRx Biopharmaceuticals and Biodel’s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
RegeneRx Biopharmaceuticals $90,000.00 268.38 $220,000.00 ($0.01) -22.00
Biodel $11.36 million 18.27 -$4.03 million N/A N/A

RegeneRx Biopharmaceuticals has higher earnings, but lower revenue than Biodel.


Biodel beats RegeneRx Biopharmaceuticals on 8 of the 11 factors compared between the two stocks.

About RegeneRx Biopharmaceuticals

RegeneRx Biopharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development of a therapeutic peptide, Thymosin beta 4 (Tb4), for tissue and organ protection, repair and regeneration. The Company’s segment is the development and marketing of product candidates based on Tb4, an amino acid peptide. The Company has formulated Tb4 into three product candidates in clinical development: RGN-259, RGN-352 and RGN-137. Tb4 is a synthetic copy of a naturally occurring 43-amino acid peptide that is originally isolated from bovine thymus glands. RGN-259 is its preservative-free eye drop formulation of Tb4. RGN-352 is an injectable formulation to treat cardiovascular diseases, central and peripheral nervous system diseases, and other medical indications that may be treated by systemic administration. RGN-137 is a topical gel for dermal wounds and reduction of scar tissue.

About Biodel

Biodel Inc. is a specialty biopharmaceutical company. The Company focuses on the development and commercialization of treatments for diabetes. The Company is engaged in developing product candidates by applying its formulation technologies to existing drugs. The Company is engaged in developing room temperature stable glucagon presentations for use as a rescue treatment for diabetes patients experiencing severe hypoglycemia. It also develops insulin formulations for Type 1 and Type 2 diabetes patients. Its product pipeline includes RHI-based Ultra-Rapid-Acting Insulin, Analog-based Ultra-Rapid-Acting Insulin, Concentrated Ultra-Rapid-Acting Insulin and Glucagon. The Company’s BIOD-531 is a Concentrated Ultra-Rapid-Acting Insulin and its insulin analog-based ultra-rapid-acting insulin product candidates include BIOD-123, BIOD-531, BIOD-238 and BIOD-250. It also conducts pre-clinical testing to develop liquid formulations of glucagon for hypoglycemic rescue and other indications.

What are top analysts saying about RegeneRx Biopharmaceuticals Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for RegeneRx Biopharmaceuticals Inc and related companies.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit